| Literature DB >> 27133044 |
Yilin Wang1, Xiaolong Zhang1, Chao Zou1, Hsiang-Fu Kung2, Marie C Lin3, Andreas Dress4, Fiona Wardle5, Bing-Hua Jiang6, Lihui Lai7.
Abstract
Angiogenesis has been found as an attractive target for drug therapy as it is necessary for tumor growth. Accumulating evidences show that microRNAs (miRNAs), which are a group of highly conserved, single-stranded, short non-coding RNAs, play important roles through directly targeting angiogenic factors and protein kinases. The purpose of this study is to investigate the role of miR-195 in breast cancer development and angiogenesis through targeting IRS1. We show that miR-195 is inversely related with Insulin receptor substrate 1 (IRS1) in both breast cancer cells and breast cancer tissues. Induction of miR-195 could suppress IRS1 protein expression through binding to its 3'UTR regions either by transfection with miR-195 oligo or by infection with lentivirus encoding miR-195 gene. Moreover, re-expression of IRS1 reverses miR-195-mediated repression of tumor cell growth and miR-195 inhibits tumor angiogenesis through suppressing IRS1-VEGF axis. These data suggest that miR-195 mimics are potential therapeutic agents for breast cancer diagnose.Entities:
Keywords: Angiogenesis; Breast cancer; Insulin receptor substrate 1; MiR-195
Mesh:
Substances:
Year: 2016 PMID: 27133044 DOI: 10.1016/j.biopha.2016.03.007
Source DB: PubMed Journal: Biomed Pharmacother ISSN: 0753-3322 Impact factor: 6.529